Alumis skin disease drug meets main goal of two late-stage trials
06/01/2026 12:04
Jan 6 (Reuters) - Alumis ALMS.O said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial